Webinar: Automate your processes

Free ZEISS webinar on January 30th, 2025.

EU Pharmaceutical Legislation Reform

The EU's Pharmaceutical Legislation Reform, proposed by the commission within the European Health Union, aims to establish a citizen-centric framework to enhanc...

Trends and overview: ELRIG "Robotics and Automation"

Laboratories on the way to end-to-end automation: Robotics, artificial intelligence and automation technology boosted by pandemic

Quality solutions for medical device R&D applications

From R&D to the quality assurance of series production in medical device manufacturing.

Clean solutions - Handling viscose substances with precision

Laboratories in the chemical, petrochemical, pharmaceutical and food technology industries are increasingly relying on automation for sample preparation. The Mo...

Webinar: Support Trial Patients Transitioning to the Commercial Space

Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.

The government proposes fines for pharmaceutical companies that fail to notify drug shortages in time

According to a compilation from the Swedish Medicines Agency, the number of residually notified medicines increased by 54 % in Sweden last year compared to the ...

40,000 DNA extractions daily

It's great when things run quickly: 20 minutes per extraction process and a new plate every 2.5 minutes – the Dutch company Synchron Lab Automation, in cooperat...

Joy at Egetis after positive CHMP opinion – ”The single most important milestone”

Stockholm-based Egetis Therapeutics has received a positive CHMP opinion for Emcitate, which could become the first approved treatment for the rare disease MCT8 deficiency."

Several departures at the top at Nykode

Members of both the management and the board are leaving the Norwegian biotech company Nykode.

Are you curious about volume imaging for very large samples?

Exciting ZEISS Webinar!

A surprising discovery about the immune system in cases of cancer

Professor Göran Jönsson is trying to understand why some patients benefit from immunotherapies while others don’t. A couple of years ago, he made a surprising d...

Unmatched performance and flexibility in its class

The new ZEISS SPECTRUM family is equipped to be the ideal match from measuring small electronics up to larger housings.

Quiet, fast, inexpensive: mass flow controller for life sciences

Whether in portable oxygen system devices or in bioreactors, the new proportional flow control valve VEMD from Festo provides extremely high control dynamics an...

Pfizer värvar FDA-topp – kritiseras hårt

Läkemedelsjätten Pfizers rekrytering av Patrizia Cavazzoni, tills helt nyligen toppchef vid FDA, som ny medicinsk chef får frän kritik från flera håll.

Tougher competition as the Novo Nordisk Foundation broadens its programme

Søren Nedergaard has worked with innovation at the Danish Government Offices and the University of Copenhagen. Today, he is COO of the Novo Nordisk Foundation, ...

Small robots to deliver pharmaceuticals to the body

Robots that can operate inside the body and a platform that combines ultrasound with AI. These are a couple of the technologies that have qualified for a list t...

Investigations against AstraZeneca: ”Chinese interests may be behind them”

Why are there several investigations against AstraZeneca employees in China right now? Life Science Sweden continues to seek answers.

TFS Trial Form Support AB

Drug development creates new challenges for regulators

From powder to implant

Quality assurance for additively manufactured implants.

Integrated solutions for liquid handling

Greater efficiency for manufacturers in laboratory automation and many other industries

Stockholm and Uppsala jointly form a life science cluster

Stockholm and Uppsala are strengthening cooperation in medical research and biotech.

Thomas Eldered: ”Innovation is the key”

Thomas Eldered speaks in a web clip about the challenges facing the life science sector in the future and what he, as an investor, finds most interesting in new companies.